Dr. Carrie Brownstein joined Cellectis in April 2020 as Chief Medical Officer, where she oversees clinical research and development and is responsible for the strategy and tactical implementation of Cellectis’ clinical stage programs from candidate selection through commercialization. Dr. Brownstein joined Cellectis as a seasoned clinical and medical expert from Celgene, where she most recently served as Vice President, Global Clinical Research and Development, Therapeutic Area Head for myeloid diseases, managing a clinical team of physicians and scientists across multiple global sites. Prior to Celgene, Dr. Brownstein served as Executive Director, Clinical Sciences Oncology at Regeneron Pharmaceuticals where she led teams investigating multiple early development programs and assets, including T-cell engaging bispecific antibodies. Dr. Brownstein started her industry career at Hoffman-La Roche (Roche Pharmaceuticals), where she held roles of increasing responsibility, and most recently served as Senior Medical Director supporting the development and approval of hematology and oncology therapies.

Prior to her industry career, Dr. Brownstein practiced medicine as a Pediatric Hematologist/Oncologist on faculty at notable New York institutions including New York Presbyterian Columbia University and Mount Sinai Medical Center. Dr. Brownstein received her M.D. from Tufts University School of Medicine and completed her internship and residency at the Babies and Children’s Hospital of Columbia Presbyterian Medical Center (NYP, Morgan Stanley Children’s Hospital) in New York, NY, and completed her fellowship in Pediatric Hematology and Oncology at Memorial Sloan Kettering Cancer Center in New York, NY.